从ascot研究看高血压综合危险控制的新组合新策略xai_p1ag.pptVIP

This shows the overall benefit of treatment. There are large reductions in deaths from stroke, CHD and vascular disease, but not increase in death from other causes. This shows the overall benefit of treatment. There are large reductions in deaths from stroke, CHD and vascular disease, but not increase in death from other causes. Implications for NORVASC In conclusion, we see that the CAMELOT/NORMALISE results offer compelling data for the use of NORVASC in patients with CAD and controlled hypertension. CAMELOT/NORMALISE data show that CAD patients, aggressively treated with statins, beta-blockers, and aspirin, may benefit significantly from the addition of NORVASC in their treatment algorithm. 从ASCOT研究看高血压综合危险控制的新组合、新策略 同济大学医学院 北京大学人民医院 胡大一教授 首都医科大学心脏病学系 构筑心血管全面防线、 应对心血管疾病浪潮 警告！ 中国心脑血管疾病的第二次浪潮！ 中国心脑血管疾病的第二次浪潮！ 中风发病率居高不下！ 脑出血减少：高血压防治出现成效 缺血性中风增加：高血压“三率”仍低，胆固醇重视和防治不够 心肌梗死发病率显著上升 胆固醇是最重要因素 心脑血管疾病年轻化 84－99年北京市成年人TC增加24％（40mg/dL) 35-44岁男性心肌梗死死亡率增加156％ 中国心脑血管疾病的第二次浪潮！ 肥胖增加！6000万！超重2亿！ 糖尿病增加！ 甜蜜的杀手！ 3000万！ 2020年，中国糖尿病患者翻倍！成为世界第二大糖尿病国家！ 代谢综合症 高血压人群增加！ 悄悄的杀手！ 1.6亿 胆固醇水平上升！高胆固醇血症人群增加！ 无声的杀手！1.6亿 National Guidelines on Hypertension and Dyslipidaemia: Importance of Multiple Risk Factor Management JNC 7: assess a patient’s other CV risk factors that may affect prognosis and guide treatment NCEP ATP III: major risk factors (exclusive of LDL-C) modify lipid goals In patients with hypertension, assess for other CV risk factors Chobanian et al. JAMA. 2003;289:2560-2572; Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497. “Attention should be moved from knowing one’s BP and cholesterol concentrations to knowing one’s absolute CV risk and its determinants.” – J. Emberson et al. Emberson et al. Eur Heart J. 2004;25:484-491. Effect of Long-Term Modest Reductions in CV Risk Factors Emberson et al. Eur Heart J. 2004;25:484-491. 10% Reductionin BP 10% Reductionin TC + 45% Reductionin CVD =